Table 3.
Comparison of patient demographic characteristics of the analysis set for secondary objective
| Tocilizumab (COVIREGI-JP) | SOC (COVIREGI-JP) | S.D. | ||
|---|---|---|---|---|
| (N = 116.00) | (N = 116.00) | |||
| Sex | Male | 81.00 (69.8%) | 83.50 (72.0%) | 0.0 |
| Female | 35.00 (30.2%) | 32.50 (28.0%) | 0.0 | |
| Age (yr) | Mean (SD) | 69.1 (13.2) | 69.5 (12.6) | 0.0 |
| Age group (yr) | 18–64 | 41.00 (35.3%) | 37.08 (32.0%) | 0.1 |
| 65–84 | 60.00 (51.7%) | 66.67 (57.5%) | –0.1 | |
| ≥85 | 15.00 (12.9%) | 12.25 (10.6%) | 0.1 | |
| Weight (kg) | Mean (SD) | 69.6 (17.1) | 69.4 (17.5) | 0.0 |
| Race | Japanese | 113.00 (97.4%) | 112.25 (96.8%) | 0.0 |
| Other (unknown) | 3.00 (2.6%) | 3.75 (3.2%) | 0.0 | |
| BMI | <25 | 45.00 (38.8%) | 47.33 (40.8%) | 0.0 |
| ≥25 | 50.00 (43.1%) | 47.42 (40.9%) | 0.0 | |
SOC Standard treatment for severe COVID-19 patients, S.D. Standardized difference, SD Standard deviation